LOS ANGELES--(BUSINESS WIRE)--June 15, 2006--Clearant, Inc. (OTCBB:CLRI - News) today announced that positive results from a study examining the safety and biomechanical integrity of tissue sterilized with the Clearant Process were published recently in the Journal of Orthopaedic Research (Volume 24, Issue 5). The study concluded that the Clearant Process method of terminal sterilization -- gamma irradiation (50kGy dose) under controlled conditions and following a treatment with radio-protective solution -- can virtually eliminate infections risks associated with soft tissue allografts while maintaining the pre-implantation biomechanical performance of the tissue. The Clearant Process is the first method capable of substantially reducing all types of pathogens in tissue implant sterilized in its final packaging, while maintaining the integrity of the essential underlying protein in the tissue.
